A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 342-351

  Mayer, Katharina ^a   Schulz, Stefanie ^a   Bernlochner, Isabell ^b   Morath, Tanja ^a   Braun, Siegmund ^a   Hausleiter, Jörg ^c   Massberg, Steffen ^c   Schunkert, Heribert ^a,d   Laugwitz, Karl Ludwig ^b,d   Kastrati, Adnan ^a,d   Sibbing, Dirk ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Clopidogrel; High platelet reactivity; Prasugrel; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; LEPIRUDIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RESUSCITATION; STENT THROMBOSIS; TELEPHONE INTERVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLEEDING; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY THROMBOSIS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SUBSTITUTION; GERMANY; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; STATISTICAL MODEL; THROMBOCYTE; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CASE-CONTROL STUDIES; CORONARY THROMBOSIS; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; GERMANY; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; RISK FACTORS; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84905190256     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0874     Document Type: Article

References (27)

1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
2. Neubauer H, Meves SH. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013; 368: 870-871.
3. Mahla E, Antonino MJ, Tantry US, et al. Point-of-care platelet function analysis ready for prime time? J Am Coll Cardiol 2009; 53: 857-859.
4. Aradi D, Komocsi A, Price MJ, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol 2013; 167: 2140-2148.
5. Trenk D, Stone GW, Gawaz M, et al. A Randomised Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59: 2159-2164.
6. Price MJ, Berger PB, Teirstein PS, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomised trial. J Am Med Assoc 2011; 305: 1097-1105.
7. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
8. Stone GW. ADAPT-DES: A Large-Scale, Prospective, Multicenter Registry Examining the Relationship of Platelet Responsiveness to Stent Thrombosis After DES Implantation. Transcatheter Cardiovascular Therapeutics 2011, San Francisco, November 9, 2011.
9. Siller-Matula JM, Francesconi M, Dechant C, et al. Personalised antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013; 167: 2018-2023.
10. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomised prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
11. Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
12. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933.
13. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
14. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardised definitions. Circulation 2007; 115: 2344-2351.
15. Siller-Matula JM, Haberl K, Prillinger K, et al. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation. Thromb Res 2009; 123: 874-880.
16. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
17. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
18. Jaitner J, Stegherr J, Morath T, et al. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011; 105: 107-112.
19. Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 2013; 110: 628-631.
20. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
21. Aradi D, Kuliczkowski W, Atar D, et al. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012; 107: 338-345.
22. Alexopoulos D, Plakomyti TE, Xanthopoulou I. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. Int J Cardiol 2012; 154: 333-334.
23. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467-473.
24. Task Force on the management of STEMI, Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
25. Serebruany V, Atar D. Prasugrel: the real-life perspective. Circ Cardiovasc Qual Outcomes 2013; 6: 253-254.
26. Tantry US, Bonello L, Aradi D, et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischaemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
27. Aradi D, Tornyos A, Pintér T, et al. Optimizing P2Y12-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014; 1061-1070.